Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ENDO INTERNATIONAL PLC ENDPQ

Healthcare Drug Manufacturers - Specialty & Generic
Endo International plc has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code and is winding down its business. The Company has no business operations.

Recent & Breaking News (GREY:ENDPQ)

Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution

PR Newswire April 22, 2024

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

PR Newswire March 26, 2024

Endo Announces Confirmation of Plan of Reorganization

PR Newswire March 19, 2024

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution

PR Newswire March 12, 2024

ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS

PR Newswire March 6, 2024

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

PR Newswire February 29, 2024

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

PR Newswire January 24, 2024

Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients

PR Newswire November 30, 2023

Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting

PR Newswire November 16, 2023

ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS

PR Newswire November 6, 2023

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

PR Newswire September 21, 2023

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

PR Newswire August 8, 2023

Endo Announces First Patient Enrolled in Registry of Peyronie's Disease

PR Newswire July 20, 2023

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

PR Newswire July 18, 2023

Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage

PR Newswire July 17, 2023

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

PR Newswire July 13, 2023

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

PR Newswire June 29, 2023

Endo Announces Approval of XCOPRI(TM) (cenobamate tablets) in Canada

PR Newswire June 29, 2023

Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture

PR Newswire June 26, 2023

Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant®

PR Newswire June 15, 2023